Long lasting drug formulations
AssigneeMedgenics Medical Israel Ltd.
InventorsAndrew L. Pearlman, Baruch S. Stern, Nir Shapir
Life of this patent
Estimating the term…
Abstract
The present invention is directed to long-lasting therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes a therapeutic polypeptide, such as erythropoietin or interferon alpha.
Claims22
A long-lasting therapeutic interferon formulation comprising at least one genetically modified micro-organ that expresses and secretes interferon, said genetically modified micro-organ comprising a vector comprising a nucleic acid sequence encoding an interferon operably linked to one or more regulatory sequences, wherein said nucleic acid encoding interferon comprises SEQ. ID. No. 1.
A method of treating hepatitis in a human subject in need over a sustained period of time comprising the steps of:
- a. providing at least one genetically modified micro-organ that expresses and secretes interferon, said genetically modified micro-organ comprising a nucleic acid sequence encoding interferon operably linked to one or more regulatory sequences;
- b. determining interferon secretion levels of said at least on genetically modified micro-organ in vitro;
- c. implanting said at least one genetically modified micro-organ in said human subject at an effective dosage;
- and either
- d. measuring interferon in the serum of said human subject, or
- e. measuring levels of hepatic virus in said human subject.
Dependencies are inferred from the claim text.